睿知中国疾病研究地图
候选清单0

正在招募胃癌II期

登记标题,引自 ClinicalTrials.gov(英文原文,暂无中文译文)

A Clinical Study of Sintilimab Combined With Chemothrapy Versus Chemotherapy as Adjuvant Therapy for Gastric/Gastroesophageal Junction Adenocarcinoma

ClinicalTrials.gov 上登记的一项胃癌开放试验,由复旦大学附属肿瘤医院牵头,本站收录的另外 0 家医院列为研究中心。

状态、分期和开始时间依据 ClinicalTrials.gov 在 2026年11月8日 的登记,登记库此后可能已有更新。能否参加由研究团队决定。不构成医疗建议。

研究团队的联系方式见登记记录。本站不转递咨询。

列出这项试验的中国大陆医院 1

登记记录中列为牵头方或研究中心、且为本站收录的医院(研究中心为开放状态)。牵头方在前,研究中心按英文名称字母排序。

  1. 牵头方(推断)复旦大学附属肿瘤医院Fudan University Shanghai Cancer Center上海医院页面

登记记录可能还列有其他研究中心(包括中国大陆以外),各中心在试验期间也可能开放或关闭。在 ClinicalTrials.gov 查看全部研究中心

来源:ClinicalTrials.gov 登记记录 NCT07492615,读取于 2026年11月8日;医院名称与本站医院名单匹配。 名称如何匹配

这项试验的核对清单 8

只列这项试验的登记记录有明确答案的要点:登记的年龄和性别,以及写明数值、评分、分期或具体检查的标准条目。与医疗资料对照后可勾选。条目为英文原文,暂无中文译文。

展开清单(8 项)收起清单
  1. 18 岁 至 未注明;性别:不限

    登记记录的入选字段

  2. Diagnosed with mismatch repair deficiency (dMMR) by immunohistochemistry (IHC) of biopsy tissue or microsatellite instability-high (MSI-H) by genetic sequencing.

    入选标准第 5 条

  3. Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class ≥2.

    排除标准第 20 条

  4. For female subjects of childbearing potential, a urine or serum pregnancy test must be negative within 3 days prior to the first dose of study drug (Cycle 1 Day 1). If the urine pregnancy test cannot be confirmed as negative, a serum pregnancy test is required. Non-childbearing potential is defined as postmenopausal for at least 1 year, or surgically sterile or hysterectomy.

    入选标准第 20 条

    If at risk of conception, all subjects (male or female) must use contraceptive measures with a failure rate of <1% per year throughout the treatment period and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).

    入选标准第 21 条

    Currently participating in interventional clinical study treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to first dose.

    排除标准第 3 条

    Prior receipt of the following therapies: anti-PD-1, anti-PD-L1, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.).

    排除标准第 4 条

    Received systemic therapy with Chinese patent medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferons, interleukins, except for local use to control pleural effusion) within 2 weeks prior to first dose.

    排除标准第 5 条

    Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.

    排除标准第 6 条

    Has not adequately recovered from toxicities and/or complications caused by any prior intervention prior to starting treatment (i.e., ≤ grade 1 or returned to baseline, excluding fatigue or alopecia).

    排除标准第 10 条

    HBV viral load <1000 copies/ml (200 IU/ml) prior to first dose, subjects should receive anti-HBV therapy during the entire study chemotherapy treatment to prevent reactivation.

    排除标准第 13 条

  5. ECOG performance status 0-1.

    入选标准第 8 条

  6. Absolute neutrophil count (ANC) ≥1.5×10\^9/L without granulocyte colony-stimulating factor within the past 14 days.

    入选标准第 11 条

    Platelets ≥100×10\^9/L without transfusion within the past 14 days.

    入选标准第 12 条

    Hemoglobin >9 g/dL without transfusion or erythropoietin use within the past 14 days.

    入选标准第 13 条

    Total bilirubin ≤1.5×ULN; if total bilirubin >1.5×ULN but direct bilirubin ≤ULN, enrollment is also permitted.

    入选标准第 14 条

    Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN.

    入选标准第 15 条

    Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min.

    入选标准第 16 条

  7. Diagnosis of any other malignant disease other than gastric cancer within 5 years prior to first dose (excluding curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected carcinoma in situ).

    排除标准第 2 条

    Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive).

    排除标准第 11 条

    For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring for viral reactivation is needed.

    排除标准第 14 条

    Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the lower limit of detection).

    排除标准第 15 条

  8. Pregnant or breastfeeding women.

    排除标准第 17 条

勾选只留在本页面,不保存、不发送。各项都符合也不等于能够参加,由研究团队经筛查后决定。需要研究团队判断的条目(如 “sufficient organ function”)不在此清单中,见下方完整标准。 本记录没有明确写出:影像与可测量病灶。

需要向研究团队确认的问题

按固定关键词规则从登记记录中选出(非 AI,未经人工核对),引自 ClinicalTrials.gov, NCT07492615,读取于 2026年11月10日。

登记的入选标准

依据 ClinicalTrials.gov 的登记,读取于 2026年11月10日,未删减。以下为英文原文,暂无中文译文。符合书面条件并不等于能够参加,由研究团队经筛查后决定。

入选标准:Inclusion Criteria:

  1. Signed written informed consent.
  2. Male or female, age ≥18 years.
  3. Histopathologically confirmed adenocarcinoma of the stomach or gastroesophageal junction (GEJ).
  4. Diagnosed with pTNM stage IIIC or pTNM stage IIIA/IIIB.
  5. Diagnosed with mismatch repair deficiency (dMMR) by immunohistochemistry (IHC) of biopsy tissue or microsatellite instability-high (MSI-H) by genetic sequencing.
  6. Underwent D2 or more extensive radical resection and achieved R0 resection.
  7. Able to swallow tablets normally.
  8. ECOG performance status 0-1.
  9. Life expectancy >6 months.
  10. Adequate organ function, subjects must meet the following laboratory criteria:
  11. Absolute neutrophil count (ANC) ≥1.5×10\^9/L without granulocyte colony-stimulating factor within the past 14 days.
  12. Platelets ≥100×10\^9/L without transfusion within the past 14 days.
  13. Hemoglobin >9 g/dL without transfusion or erythropoietin use within the past 14 days.
  14. Total bilirubin ≤1.5×ULN; if total bilirubin >1.5×ULN but direct bilirubin ≤ULN, enrollment is also permitted.
  15. Aspartate aminotransferase (AST) and alanine aminotransferase (ALT) ≤2.5×ULN.
  16. Serum creatinine ≤1.5×ULN and creatinine clearance (calculated by Cockcroft-Gault formula) ≥60 ml/min.
  17. Good coagulation function, defined as international normalized ratio (INR) or prothrombin time (PT) ≤1.5×ULN.
  18. Normal thyroid function, defined as thyroid-stimulating hormone (TSH) within normal range. If baseline TSH is outside the normal range, subjects with total T3 (or FT3) and FT4 within the normal range may also be enrolled.
  19. Cardiac enzyme panel within normal range (isolated laboratory abnormalities deemed clinically insignificant by the investigator are also permitted for enrollment).
  20. For female subjects of childbearing potential, a urine or serum pregnancy test must be negative within 3 days prior to the first dose of study drug (Cycle 1 Day 1). If the urine pregnancy test cannot be confirmed as negative, a serum pregnancy test is required. Non-childbearing potential is defined as postmenopausal for at least 1 year, or surgically sterile or hysterectomy.
  21. If at risk of conception, all subjects (male or female) must use contraceptive measures with a failure rate of <1% per year throughout the treatment period and for 120 days after the last dose of study drug (or 180 days after the last dose of chemotherapy).

排除标准:Exclusion Criteria:

  1. Cancers involving the EGJ with the tumor center located in the proximal stomach ≤2 cm from the EGJ.
  2. Diagnosis of any other malignant disease other than gastric cancer within 5 years prior to first dose (excluding curatively treated basal cell carcinoma of the skin, squamous cell carcinoma of the skin, and/or curatively resected carcinoma in situ).
  3. Currently participating in interventional clinical study treatment, or has received other investigational drugs or used investigational devices within 4 weeks prior to first dose.
  4. Prior receipt of the following therapies: anti-PD-1, anti-PD-L1, or drugs targeting another stimulatory or co-inhibitory T-cell receptor (including but not limited to CTLA-4, OX-40, CD137, etc.).
  5. Received systemic therapy with Chinese patent medicines with anti-tumor indications or immunomodulatory drugs (including thymosin, interferons, interleukins, except for local use to control pleural effusion) within 2 weeks prior to first dose.
  6. Active autoimmune disease requiring systemic treatment (e.g., disease-modifying drugs, corticosteroids, or immunosuppressants) within 2 years prior to first dose. Replacement therapy (e.g., thyroxine, insulin, or physiological corticosteroids for adrenal or pituitary insufficiency) is not considered systemic treatment.
  7. Receiving systemic corticosteroid therapy (excluding nasal spray, inhaled, or other topical corticosteroids) or any other form of immunosuppressive therapy within 7 days prior to first dose.
  8. Known allogeneic organ transplantation (except corneal transplantation) or allogeneic hematopoietic stem cell transplantation.
  9. Known allergy to any drug used in this study.
  10. Has not adequately recovered from toxicities and/or complications caused by any prior intervention prior to starting treatment (i.e., ≤ grade 1 or returned to baseline, excluding fatigue or alopecia).
  11. Known history of human immunodeficiency virus (HIV) infection (i.e., HIV 1/2 antibody positive).
  12. Untreated active hepatitis B (defined as HBsAg positive and HBV-DNA copy number above the upper limit of normal of the testing laboratory at the study site). Subjects meeting the following criteria may also be enrolled:
  13. HBV viral load <1000 copies/ml (200 IU/ml) prior to first dose, subjects should receive anti-HBV therapy during the entire study chemotherapy treatment to prevent reactivation.
  14. For subjects with anti-HBc (+), HBsAg (-), anti-HBs (-) and HBV viral load (-), prophylactic anti-HBV therapy is not required, but close monitoring for viral reactivation is needed.
  15. Subjects with active HCV infection (HCV antibody positive and HCV-RNA level above the lower limit of detection).
  16. Received a live vaccine within 30 days prior to first dose (Cycle 1, Day 1).
  17. Pregnant or breastfeeding women.
  18. Presence of any severe or uncontrolled systemic disease, such as:
  19. Abnormalities in resting ECG in rhythm, conduction, or morphology that are significant and severely symptomatic and difficult to control, such as complete left bundle branch block, second-degree or higher heart block, ventricular arrhythmias, or atrial fibrillation.
  20. Unstable angina, congestive heart failure, chronic heart failure with New York Heart Association (NYHA) class ≥2.
  21. Any arterial thrombotic, embolic, or ischemic event within 6 months prior to enrollment, such as myocardial infarction, unstable angina, cerebrovascular accident, or transient ischemic attack.
  22. Uncontrolled hypertension (systolic blood pressure >140 mmHg, diastolic blood pressure >90 mmHg).
  23. History of non-infectious pneumonitis requiring corticosteroid treatment within 1 year prior to first dose, or current clinically active interstitial lung disease.
  24. Active pulmonary tuberculosis.
  25. Active or uncontrolled infection requiring systemic therapy.
  26. Clinically active diverticulitis, intra-abdominal abscess, gastrointestinal obstruction.
  27. Liver diseases such as cirrhosis, decompensated liver disease, acute or chronic active hepatitis.
  28. Poorly controlled diabetes (fasting blood glucose (FBG) >10 mmol/L).
  29. Urinalysis indicates proteinuria ≥++ and confirmed 24-hour urine protein quantification >1.0 g.
  30. Patients with mental disorders who are unable to comply with treatment.
  31. History or evidence of disease, treatment, or laboratory abnormalities that may interfere with the study results, hinder the subject's full participation in the study, or other conditions that the investigator deems unsuitable for enrollment, or the investigator believes there are other potential risks that make participation inappropriate.

引自 ClinicalTrials.gov, NCT07492615, 参与标准,读取于 2026年11月10日。

这些信息从哪里来

登记记录

ClinicalTrials.gov(美国国家医学图书馆),登记记录 NCT07492615,读取于 2026年11月8日。总体状态为正在招募、即将招募或邀请入组、且至少有一家列出医院的研究中心开放的试验,在本站有单独页面。仅在中国临床试验注册中心(ChiCTR)登记的试验没有计入。

疾病与医院

本站在 ClinicalTrials.gov 按疾病检索中国的试验,检索到这项试验,就把它列在该病下。登记记录中的牵头方和研究中心名称与本站医院名单匹配(ROR 编号与核对过的别名)。 定义

没有收录的内容

登记记录中研究者和联系人的姓名,以及记录之外的任何信息。标题和入选标准引自登记记录。

提出更正ClinicalTrials.gov NCT07492615